Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

CJC Open is a leading open access journal published by Elsevier, focused on advancing the fields of Cardiology and Cardiovascular Medicine. Since its inception in 2019, the journal has committed to disseminating high-quality research and groundbreaking advancements in cardiovascular health. With its ISSN 2589-790X and an impressive Q2 ranking in its field, CJC Open aims to foster collaboration and communication among researchers, healthcare professionals, and students by providing a platform for innovative studies, reviews, and insights. The journal is indexed in Scopus, currently ranking at #191 out of 387 in its category, underscoring its relevance and impact in the academic community. As an open access journal, CJC Open ensures that research findings are widely available, promoting greater visibility and readership. Scientists and practitioners alike are encouraged to submit their work, further enriching the discourse in cardiovascular research. With a focus on quality and accessibility, CJC Open is poised to make significant contributions to the field through 2024 and beyond.

PROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Future Cardiology, published by Future Medicine Ltd, is an esteemed journal dedicated to advancing the field of cardiology and cardiovascular medicine. With an ISSN of 1479-6678 and an E-ISSN of 1744-8298, this journal has been serving as a vital platform for researchers and healthcare professionals since its inception in 2006. The journal features rigorously peer-reviewed articles, offering insights into innovative treatments, clinical studies, and cutting-edge research developments. Although it is currently categorized as Q3 in Cardiology and Cardiovascular Medicine and Q4 in Molecular Medicine, its growing impact is evident in its dedicated audience and commitment to fostering dialogue in the cardiovascular community. Future Cardiology provides an invaluable opportunity for scholars to share their findings and enhance knowledge in this critical area of healthcare, a pursuit that is ever more important as cardiovascular diseases continue to be a leading health concern worldwide. Access options are through standard subscriptions, allowing in-depth exploration of articles that push the boundaries of cardiological science.

ARYA Atherosclerosis is a distinguished open-access journal published by Isfahan University of Medical Sciences and the Isfahan Cardiovascular Research Center, with an ISSN of 1735-3955 and an E-ISSN of 2251-6638. Founded in 2005, this journal seeks to advance the field of cardiology and cardiovascular medicine by providing a platform for researchers, healthcare professionals, and scholars to disseminate groundbreaking findings related to atherosclerosis and its implications for cardiovascular health. Although currently ranked in Q4 of its category in 2023, ARYA Atherosclerosis plays a vital role in the academic community by promoting open access to vital research, fostering collaboration, and encouraging the sharing of knowledge. The journal's commitment to transparency and accessibility makes it an essential resource for those looking to stay informed about the latest developments in cardiovascular research. Based in Iran, it is positioned within an emerging research landscape that is increasingly contributing to global health discussions.

Acta Cardiologica Sinica is a distinguished journal dedicated to the advancement of cardiology and cardiovascular medicine, published by the Taiwan Society of Cardiology. Since its inception in 1988, this journal has provided a platform for researchers and clinicians to share cutting-edge findings and insights into cardiac health, cardiovascular diseases, and innovative treatment strategies. With an impressive Q3 classification in the Cardiology category for 2023, the journal is recognized for its contributions to the field, ranked #208 out of 387 in Scopus, placing it within the 46th percentile of medical journals. Although it currently does not offer open access options, it remains a valued resource for the global cardiovascular community. The journal's commitment to disseminating high-quality research papers, reviews, and case studies ensures that it plays a vital role in improving cardiovascular health practices and outcomes. For researchers, professionals, and students alike, Acta Cardiologica Sinica is essential reading for staying informed about the latest developments in cardiology.

Welcome to the Journal of Cardiovascular Medicine, a leading platform for the dissemination of high-quality research in the field of cardiology and cardiovascular medicine. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an ISSN of 1558-2027 and an E-ISSN of 1558-2035, reflecting its commitment to accessible and innovative cardiovascular research. With a significant impact factor and ranked Q2 in both Cardiology and Cardiovascular Medicine as well as in Medicine (Miscellaneous) for 2023, the journal is recognized for its contributions to advancing knowledge and practice in this critical area of health. The journal disseminates original research, reviews, and clinical studies, aimed at clinicians, researchers, and healthcare professionals who are dedicated to improving cardiovascular health outcomes. With a continuous commitment to evolving research from 2006 to 2024, the journal is an essential resource for those looking to stay at the forefront of the latest discoveries and methodologies in cardiovascular medicine.

Revista de la Federacion Argentina de Cardiologia is a vital publication in the field of Cardiology and Cardiovascular Medicine, providing a platform for researchers and healthcare professionals to share significant findings and innovative concepts since its inception in 2012. Published by the Federacion Argentina Cardiology, this journal specifically addresses contemporary issues and advancements within cardiology, contributing to the scholarly dialogue essential for improving cardiovascular health. Despite being categorized in the Q4 quartile for 2023 and presently ranking #358 out of 387 in its field, the journal remains committed to fostering academic inquiry and disseminating valuable research for both local and global audiences. Although it is not an open-access journal, it strives to balance accessibility with rigorous academic standards, ensuring quality contributions that are critical for practitioners and students alike. The journal’s ongoing evaluation and adaptation in the ever-evolving landscape of cardiology underscore its importance in advancing cardiovascular science and practice.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.